Search research articles
Contact Us
Filters
Showing results (61-70 of 69) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 69 results.
Antimicrobial Agents and Chemotherapy
|
May 17, 2001
Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus
W E Delaney, R Edwards, D Colledge, et al.
Gut
|
November 2, 2010
Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B
S J Patterson, J George, S I Strasser, et al.
The Journal of Infectious Diseases
|
October 27, 2001
Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection
R J Colonno, E V Genovesi, I Medina, et al.
Bioorganic & Medicinal Chemistry
|
September 11, 1999
Synthesis and evaluation of 2-amino-9-(3-acyloxymethyl-4-alkoxycarbonyloxybut-1-yl)purines and 2-amino-9-(3-alkoxycarbonyloxymethyl-4-alkoxycarbonyloxybut-1- yl)purines as potential prodrugs of penciclovir
D K Kim, N Lee, D H Ryu, et al.
Journal of Viral Hepatitis
|
October 6, 2015
Toll-IL1 receptor-mediated innate immune responses vary across HBV genotype and predict treatment response to pegylated-IFN in HBeAg-positive CHB patients
K Visvanathan, T Lang, K Ryan, et al.
Alimentary Pharmacology & Therapeutics
|
October 13, 2017
HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients
D Wong, M Littlejohn, L Yuen, et al.
Journal of Medical Virology
|
July 22, 2010
High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B
M C Mendes-Correa, J R R Pinho, S Locarnini, et al.
Antimicrobial Agents and Chemotherapy
|
August 26, 2004
Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine
D J Tenney, S M Levine, R E Rose, et al.
Hepatology International
|
November 14, 2015
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
S K Sarin, M Kumar, G K Lau, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 69) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 69 results.
Antimicrobial Agents and Chemotherapy
|
May 17, 2001
Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus
W E Delaney, R Edwards, D Colledge, et al.
Gut
|
November 2, 2010
Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B
S J Patterson, J George, S I Strasser, et al.
The Journal of Infectious Diseases
|
October 27, 2001
Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection
R J Colonno, E V Genovesi, I Medina, et al.
Bioorganic & Medicinal Chemistry
|
September 11, 1999
Synthesis and evaluation of 2-amino-9-(3-acyloxymethyl-4-alkoxycarbonyloxybut-1-yl)purines and 2-amino-9-(3-alkoxycarbonyloxymethyl-4-alkoxycarbonyloxybut-1- yl)purines as potential prodrugs of penciclovir
D K Kim, N Lee, D H Ryu, et al.
Journal of Viral Hepatitis
|
October 6, 2015
Toll-IL1 receptor-mediated innate immune responses vary across HBV genotype and predict treatment response to pegylated-IFN in HBeAg-positive CHB patients
K Visvanathan, T Lang, K Ryan, et al.
Alimentary Pharmacology & Therapeutics
|
October 13, 2017
HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients
D Wong, M Littlejohn, L Yuen, et al.
Journal of Medical Virology
|
July 22, 2010
High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B
M C Mendes-Correa, J R R Pinho, S Locarnini, et al.
Antimicrobial Agents and Chemotherapy
|
August 26, 2004
Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine
D J Tenney, S M Levine, R E Rose, et al.
Hepatology International
|
November 14, 2015
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
S K Sarin, M Kumar, G K Lau, et al.
Page
of 7